Skip to main content
. Author manuscript; available in PMC: 2024 Nov 1.
Published in final edited form as: J Immunol. 2023 Nov 1;211(9):1340–1347. doi: 10.4049/jimmunol.2300317

Figure 6. Jagged1 level is decreased in RA PBMCs and recombinant Jagged1 inhibits human inflammatory osteoclastogenesis.

Figure 6

A) Immunoblot analysis of Jagged1 expression in human CD14(+) monocytes primed with or without TGFβ for 3 days, followed by TNFα stimulation for the indicated time periods. GAPDH was blotted as the loading control. B, C) qPCR analysis of JAG1 (B), and ACP5 and CTSK (C) expression from human CD14(+) monocytes primed with or without TGFβ for 3 days, followed by TNFα stimulation for the indicated time periods (n=12/group). D) Normalized Signal Intensity of JAG1 in SLE and RA PBMCs obtained from microarray data. n=82 for SLE patients and n=84 for RA patients. E) Osteoclast differentiation derived from human CD14(+) monocytes primed with or without TGFβ for 3 days, followed by TNFα in the presence or absence of recombinant human Jagged1 (200 ng/ml) for 7 days. Left: TRAP staining. Scale bar: 200 μm. Right: Quantification of TRAP-positive MNCs displayed as % of total TRAP+ MNCs. Data are mean ± SD. *p < 0.05; **p < 0.01; n.s., not statistically significant.